Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope

Journal of Virology

Volumn 77, Issue 13, 2003, Pages 7669-7672

  Kilgore, Nicole R ^a   Salzwedel, Karl ^a   Reddick, Mary ^a   Allaway, Graham P ^a   Wild, Carl T ^a  

^a Panacos Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEX FORMATION; DRUG BINDING; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS INHIBITION;

AMINO ACID SEQUENCE; C-PEPTIDE; HIV ENVELOPE PROTEIN GP41; HIV-1; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0038467539     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.13.7669-7672.2003     Document Type: Article

References (22)

1. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
2. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
3. Chen, S. S. 1994. Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 68:2002-2010.
4. de Rosny, E., R. Vassell, P. T. Wingfield, C. T. Wild, and C. D. Weiss. 2001. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoproteins. J. Virol. 75:8859-8863.
5. Dubay, J. W., S. J. Roberts, B. Brody, and E. Hunter. 1992. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 66:4748-4756.
6. Earl, P. L., C. C. Broder, R. W. Doms, and B. Moss. 1997. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71:2674-2684.
7. Furuta, R. A., C. Wild, Y. Weng, and C. D. Weiss. 1998. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:276-279.
8. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem. Biophys. Res. Commun. 195:533-538.
9. Kliger, Y., S. A. Gallo, S. G. Peisajovich, I. Munoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai. 2001. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 276:1391-1397.
10. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
11. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
12. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031-4034.
13. Park, E. J., and G. V. Quinnan, Jr. 1999. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J. Virol. 73:5707-5713.
14. Poumbourios, P., K. A. Wilson, R. J. Center, W. El Ahmar, and B. E. Kemp. 1997. Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J. Virol. 71:2041-2049.
15. Poumbourios, P., W. el Ahmar, D. A. McPhee, and B. E. Kemp. 1995. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J. Virol. 69:1209-1218.
16. Ryu, J. R., B. S. Jin, M. J. Suh, Y. S. Yoo, S. H. Yoon, E. R. Woo, and Y. G. Yu. 1999. Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. Biochem. Biophys. Res. Commun. 265:625-629.
17. Salzwedel, K., J. T. West, and E. Hunter. 1999. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73:2469-2480.
18. Weissenhorn, W., A. Dessen, L. J. Calder, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1999. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 6:3-9.
19. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
20. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrovir. 9:1051-1053.
21. Wild, C., T. Greenwell, D. Shugars, L. Rimsky-Clark, and T. Matthews. 1995. The inhibitory activity of a HIV-1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retrovir. 11:323-325.
22. Wild, C. T., D. C. Shugars, T. Greenwell, C. McDanal, and T. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.